Literature DB >> 9771441

Immunophenotypic and genotypic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO (UCHL-1).

D M Menke1, H P Horny, H Griesser, E J Atkinson, E Kaiserling, R A Kyle.   

Abstract

AIMS: To investigate whether plasma cell expression of early B cell, late B cell/preplasma cell, T cell, and myelomonocytic antigens or myeloma associated lymphocytic infiltrates correlated with prognosis in bone marrow biopsy specimens of patients with multiple myeloma.
METHODS: Bone marrow biopsy specimens of 23 patients with multiple myeloma were investigated for plasma cell expression and interstitial lymphocyte expression of T cell related antigen CD45RO (UCHL-1).
RESULTS: Eight patients showed plasma cell expression of CD45RO and 16 showed increased tumour infiltrating CD45RO positive lymphocytes, which were correlated with poor survival by multivariate analyses (p = 0.005 and p = 0.04, respectively). B cell antigens (MB2, CD20) but no T cell specific antigens (CD3) or T cell receptor gene rearrangements were expressed by plasma cells in CD45RO positive myelomas. Of 16 patients with myeloma who had increased tumour infiltrating CD45RO positive lymphocytes, four had interstitial lymphocyte expression of B cell antigens and two had interstitial lymphocyte expression of the T cell specific antigen CD3.
CONCLUSIONS: The recognition of plasma cell expression of CD45RO and increased interstitial CD45RO lymphocytes in bone marrow biopsy specimens of patients with multiple myeloma is an adverse prognostic finding not indicative of an aberrant T cell phenotype or genotype; it is consistent with B cell/pre-plasma cell antigen expression by myeloma cells and their lymphocytic precursors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9771441      PMCID: PMC500745          DOI: 10.1136/jcp.51.6.432

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  35 in total

1.  Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  M F Dehou; R Schots; P Lacor; N Arras; P Verhavert; G Klöppel; B van Camp
Journal:  Am J Clin Pathol       Date:  1990-09       Impact factor: 2.493

2.  Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction.

Authors:  K J Trainor; M J Brisco; J H Wan; S Neoh; S Grist; A A Morley
Journal:  Blood       Date:  1991-07-01       Impact factor: 22.113

3.  T-cell antigen-positive multiple myeloma.

Authors:  C M Spier; T M Grogan; B G Durie; L C Richter; E Vela; Y Frutiger; C S Rangel
Journal:  Mod Pathol       Date:  1990-05       Impact factor: 7.842

4.  Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival.

Authors:  P Omedé; M Boccadoro; G Gallone; R Frieri; S Battaglio; V Redoglia; A Pileri
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

5.  Genotypic and phenotypic characteristics of multiple myeloma.

Authors:  B Barlogie; J Epstein; R Alexanian
Journal:  Hematol Oncol       Date:  1988 Apr-Jun       Impact factor: 5.271

6.  Transition in CD45 isoform expression during differentiation of normal and abnormal B cells.

Authors:  G S Jensen; S Poppema; M J Mant; L M Pilarski
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

7.  Monoclonality in B cell lymphoma detected in paraffin wax embedded sections using the polymerase chain reaction.

Authors:  J H Wan; K J Trainor; M J Brisco; A A Morley
Journal:  J Clin Pathol       Date:  1990-11       Impact factor: 3.411

8.  Markers of multiple hematopoietic-cell lineages in multiple myeloma.

Authors:  J Epstein; H Q Xiao; X Y He
Journal:  N Engl J Med       Date:  1990-03-08       Impact factor: 91.245

9.  Myelomonocytic antigen positive multiple myeloma.

Authors:  T M Grogan; B G Durie; C M Spier; L Richter; E Vela
Journal:  Blood       Date:  1989-02-15       Impact factor: 22.113

10.  Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.

Authors:  R D Brown; D E Joshua; R A Ioannidis; H Kronenberg
Journal:  Aust N Z J Med       Date:  1989-06
View more
  2 in total

1.  Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation.

Authors:  B K Arendt; D K Walters; X Wu; R C Tschumper; P M Huddleston; K J Henderson; A Dispenzieri; D F Jelinek
Journal:  Leukemia       Date:  2012-03-30       Impact factor: 11.528

2.  Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility.

Authors:  Bin Li; Steven A Eschrich; Anders Berglund; Melissa Mitchell; David Fenstermacher; Hadi Danaee; Hongyue Dai; Daniel Sullivan; William L Trepicchio; William S Dalton
Journal:  JMIR Res Protoc       Date:  2017-03-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.